HC Wainwright Issues Optimistic Outlook for SANA Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Stock analysts at HC Wainwright boosted their Q3 2024 earnings estimates for shares of Sana Biotechnology in a report issued on Tuesday, November 5th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.09) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.61) EPS.

Several other research firms have also weighed in on SANA. Citigroup lifted their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday.

Sana Biotechnology Trading Down 9.1 %

Shares of NASDAQ SANA opened at $3.10 on Thursday. The firm has a market capitalization of $689.64 million, a PE ratio of -2.72 and a beta of 1.44. Sana Biotechnology has a 1 year low of $2.85 and a 1 year high of $12.00. The firm’s 50-day moving average is $4.33 and its 200-day moving average is $5.86.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04).

Insider Buying and Selling

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 31.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors have recently modified their holdings of SANA. Blue Trust Inc. boosted its position in shares of Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after acquiring an additional 12,154 shares during the period. Cornercap Investment Counsel Inc. bought a new stake in shares of Sana Biotechnology in the third quarter valued at about $67,000. Algert Global LLC bought a new stake in shares of Sana Biotechnology in the second quarter valued at about $73,000. XTX Topco Ltd bought a new stake in Sana Biotechnology during the second quarter worth about $100,000. Finally, Dark Forest Capital Management LP lifted its position in Sana Biotechnology by 112.0% during the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after purchasing an additional 14,430 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.